Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | LTA4H | P09960 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725064 | 0.85 | KMT2A (0.80) | LMNALTA4HKMT2AMEN1L3MBTL1 | |
| SCHEMBL9097535 | 0.85 | CA12 (0.59) | LMNAKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL62657 | 0.85 | CA12 (0.59) | LMNAKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL204877 | 0.85 | CA12 (0.59) | LMNAKMT2AMEN1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL28795867 | 0.83 | KMT2A (0.76) | LMNALTA4HKMT2AMEN1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL8640288 | 0.83 | CA12 (0.57) | LMNAKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL4190482 | 0.82 | LMNA (0.63) | LMNALTA4HKMT2AMEN1L3MBTL1 | |
| SCHEMBL11714308 | 0.79 | LMNA (0.55) | LMNALTA4HKMT2AMEN1L3MBTL1 | |
| SCHEMBL3522195 | 0.79 | LMNA (0.71) | LMNALTA4HKMT2AMEN1L3MBTL1 | |
| SCHEMBL18906029 | 0.79 | NAPRT (0.81) | LMNALTA4HKMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| CN-114144410-A | Polyarylurea derivatives and their use in the treatment of muscular diseases | 阿纳格纳斯生物技术股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20180016240-A1 | SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS | XCOVERY HOLDINGS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20180016240-A1 | SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS | XCOVERY HOLDINGS, INC. | 2018-01-18 | — | — | US | disclosed |
| EP-1844020-B1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2625176-B1 | SUBSTITUTUTED 6-AMINO-PYRIDAZIN-3-YL-CARBOXAMIDE COMPOUNDS AS PROTEIN KINASE MODULATORS | XCOVERY HOLDING CO LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160068493-A1 | SUBSTITUTED PYRIDAZINE CARBOXIMIDE COMPOUNDS | XCOVERY HOLDINGS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160068493-A1 | SUBSTITUTED PYRIDAZINE CARBOXIMIDE COMPOUNDS | XCOVERY HOLDINGS, INC. | 2016-03-10 | — | — | US | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060019990-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER HEALTHCARE LLC | 2006-01-26 | — | — | US | disclosed |
| US-20050124664-A1 | Urea thiadiazole inhibitors of plasminogen activator inhibior-1 | BRISTOL-MYERS SQUIBB CO. | 2005-06-09 | — | — | US | disclosed |
| EP-1379507-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1379505-A2 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | Bayer Corporation (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030207914-A1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2002085859-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002085857-A2 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | BAYER CORPORATION | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016240-A1 | SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS | ALK, MAP4K2, MAP3K15 | LMNA 3584/4885LTA4H 3394/4885KMT2A 290/4885 |
| US-20060019990-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BRAF, RAF1, ARAF | LMNA 2538/4885LTA4H 3649/4885KMT2A 2313/4885 |
| US-20050124664-A1 | Urea thiadiazole inhibitors of plasminogen activator inhibior-1 | SERPINE1, SERPINC1, SERPINB1 | LMNA 1497/4885LTA4H 828/4885KMT2A 4128/4885 |
| US-20030207914-A1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BRAF, RAF1, ARAF | LMNA 2542/4885LTA4H 3690/4885KMT2A 2204/4885 |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | MAPK1, MAP3K1, MAPK3 | LMNA 3261/4885LTA4H 4250/4885KMT2A 3163/4885 |
| US-20160068493-A1 | SUBSTITUTED PYRIDAZINE CARBOXIMIDE COMPOUNDS | ALK, MAP4K2, MAP3K15 | LMNA 3723/4885LTA4H 3702/4885KMT2A 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.